Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
CSPC Pharmaceutical Group ( (HK:1093) ) has provided an update.
CSPC Pharmaceutical Group Limited has announced that its Regorafenib Tablets have received drug registration approval from the National Medical Products Administration in China. This approval enhances the company’s oncology portfolio, potentially strengthening its market position in the treatment of various cancers, including metastatic colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group Limited is a company based in Hong Kong that operates in the pharmaceutical industry. It develops and manufactures a wide range of pharmaceutical products, with a focus on oncology therapies.
YTD Price Performance: -3.70%
Average Trading Volume: 7,366
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $6.57B
See more data about 1093 stock on TipRanks’ Stock Analysis page.
